Protagonist Therapeutics, specializing in orally bioavailable constrained peptides, has seen stark swings in financial performance with a significant operating loss in 2025 contrasting prior profitability. Their pipeline, anchored by Phase 3 injectable Rusfertide and licensed oral IL-23 antagonist Icotyde, is supported by collaborations with Janssen Biotech and Takeda. Despite a robust liquidity position reflected in a strong current ratio and positive free cash flow, the company faces risks tied to regulatory approvals and partner reliance. Upcoming clinical milestones could materially impact trajectory but the balance between innovation promises and commercial execution challenges remains delicate.